Dasatinib – Forschung

Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.

García-Ferrer M, Wojnicz A, Mejía G, Koller D, Zubiaur P, Abad-Santos F · Clin Ther (2019)

Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity.

Calizo RC, Bhattacharya S, van Hasselt JGC, Wei C, Wong JS, Wiener RJ · Nat Commun (2019)

Dasatinib-Associated Chylothorax: A Scoping Review and Pharmacovigilance Analysis

Einfach gesagt: Further studies using large retrospective administrative databases are warranted to formally evaluate this potential association.

Castellana E, Budau PM, Miglietta C, Milla P, Chiappetta MR. · Therapeutic innovation & regulatory science (2026)

Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

Shen S, Chen X, Cai J, Yu J, Gao J, Hu S · JAMA Oncol (2020)

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.

Hughes TP, Saglio G, Quintás-Cardama A, Mauro MJ, Kim DW, Lipton JH · Leukemia (2015)

Long-term results of frontline dasatinib in chronic myeloid leukemia.

Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F · Cancer (2020)

Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects.

Wang Y, Xue J, Su Z, Cui Y, Liu G, Yang W · Expert Opin Investig Drugs (2023)

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.

Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G · Cancer Med (2018)

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study.

Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X · Leukemia (2020)

Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report.

Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M · Int J Hematol (2017)

Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R · J Clin Invest (2016)

[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase].

Kong J, Chen N, Fu HX, Hang TJ, Song M, Jiang H · Zhonghua Xue Ye Xue Za Zhi (2016)

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J · Am J Hematol (2016)

Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.

Corbacioglu S, Lode H, Ellinger S, Zeman F, Suttorp M, Escherich G · Lancet Oncol (2024)

Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology Platform.

Lennernäs H, Brisander M, Liljebris C, Jesson G, Andersson P · Clin Pharmacol Drug Dev (2024)

Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma.

Storkus WJ, Maurer D, Lin Y, Ding F, Bose A, Lowe D · J Immunother Cancer (2021)

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C · J Clin Oncol (2016)

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.

Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP · Haematologica (2019)

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.

Creelan BC, Gray JE, Tanvetyanon T, Chiappori AA, Yoshida T, Schell MJ · Br J Cancer (2019)

Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC).

Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D · Clin Genitourin Cancer (2019)